David A. Siegel Catalyst Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,892 shares of CPRX stock, worth $224,375. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,892

Holding current value

$224,375

% of portfolio

0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $165,449 - $232,544	10,892 New	10,892 $216,000
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $10.9 Million - $17.1 Million	-944,300 Reduced 59.85%	633,392 $8.51 Million
Q1 2023 May 15, 2023	SELL	$14.34 - $21.05 $3.35 Million - $4.91 Million	-233,300 Reduced 12.88%	1,577,692 $26.2 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $2.54 Million - $4.05 Million	207,500 Added 12.94%	1,810,992 $33.7 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $3.71 Million - $8.17 Million	526,200 Added 48.84%	1,603,492 $20.6 Million
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $976,241 - $1.34 Million	-156,700 Reduced 12.7%	1,077,292 $7.55 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $1.82 Million - $2.85 Million	342,800 Added 38.47%	1,233,992 $10.2 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $2.53 Million - $3.61 Million	485,000 Added 119.4%	891,192 $6.03 Million
Q3 2021 Nov 15, 2021	SELL	$4.85 - $6.04 $1.38 Million - $1.72 Million	-284,000 Reduced 41.15%	406,192 $2.15 Million
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $885,456 - $1.25 Million	-206,400 Reduced 23.02%	690,192 $3.97 Million
Q1 2021 May 17, 2021	BUY	$3.45 - $4.69 $580,290 - $788,858	168,200 Added 23.09%	896,592 $4.13 Million
Q4 2020 Feb 16, 2021	SELL	$2.97 - $3.83 $17,523 - $22,597	-5,900 Reduced 0.8%	728,392 $2.43 Million
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $1.07 Million - $1.83 Million	-360,300 Reduced 32.92%	734,292 $2.18 Million
Q2 2020 Aug 14, 2020	BUY	$3.48 - $5.05 $2.27 Million - $3.3 Million	653,400 Added 148.1%	1,094,592 $5.06 Million
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $41,499 - $82,839	-15,900 Reduced 3.48%	441,192 $1.7 Million
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $1.63 Million - $2.53 Million	444,200 Added 3445.55%	457,092 $1.71 Million
Q3 2019 Nov 14, 2019	BUY	$3.89 - $7.43 $50,149 - $95,787	12,892 New	12,892 $68,000
Q1 2019 May 15, 2019	SELL	$2.11 - $5.33 $21,100 - $53,300	-10,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.92 - $3.62 $92,544 - $174,484	-48,200 Reduced 82.82%	10,000 $19,000
Q3 2018 Nov 14, 2018	SELL	$2.81 - $3.78 $79,804 - $107,352	-28,400 Reduced 32.79%	58,200 $220,000
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $45,877 - $77,952	20,300 Added 30.62%	86,600 $270,000
Q1 2018 May 15, 2018	SELL	$2.39 - $4.01 $28,182 - $47,285	-11,792 Reduced 15.1%	66,300 $158,000
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $196,010 - $343,604	78,092	78,092 $305,000

Others Institutions Holding CPRX

# of Institutions

326

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account